Not Losing Weight on Mounjaro 5mg? Here's What's Actually Going On

You've just moved up from 2.5mg, and your body needs time to catch up

Picture this: your first pen at 2.5mg felt like not much happened. You titrated to 5mg, half-expecting the scales to shift quickly. A fortnight passes. Then another. The number barely moves.

This is one of the most common experiences people report on Mounjaro, and it has a straightforward explanation. The 2.5mg starting dose exists purely to let your digestive system adjust, it's not there to drive weight loss. When you step to 5mg, you're at the first dose that begins to do meaningful metabolic work, but you're still in the lower range of the licensed schedule, which runs all the way to 15mg. Most participants in the SURMOUNT-1 trial who reached the highest doses saw the largest reductions; at lower doses, results were real but more modest. If you're curious how results compare across the full range, the evidence at 15mg puts the 5mg picture in context.

It also takes several weeks at a new dose for tirzepatide's full effect to establish itself. Your body's GIP and GLP-1 receptors are adapting; appetite suppression deepens gradually. A plateau in weeks three or four at 5mg is normal, not a sign that the medicine isn't working for you.

The clinical reasons the scales don't always move in a straight line

Weight loss on any GLP-1 or dual-agonist medicine is rarely linear. The NHS patient information for tirzepatide describes the expected titration pattern and notes that results build over months, not weeks. Several things can hold back progress at the 5mg level specifically.

First, energy intake. Tirzepatide reduces appetite substantially for most people, but it doesn't eliminate the need to eat less than you expend. Some people find that at 5mg the appetite reduction isn't yet strong enough to offset previous eating patterns, particularly if meals have shifted in composition rather than overall size. Protein adequacy matters here too, low protein can increase lean-mass loss rather than fat loss, which shows up poorly on a standard bathroom scale.

Second, water retention and body-composition changes. Scales measure everything: fat, muscle, water, what you ate this morning. During the first months on tirzepatide, some people lose fat while retaining slightly more water, particularly around menstruation. The number stays flat even though composition is shifting. Waist measurements and how clothes fit are often more informative than the daily weigh-in.

Third, the dose may simply not yet be optimal for you. The Mounjaro dose schedule is designed to step up every four weeks; 5mg is a waypoint, not a destination for most people. Your prescriber decides whether and when to titrate further, based on your response and tolerability.

What you can review while you wait for your next clinical check

There are practical things worth looking at before concluding that 5mg isn't working. Timing matters more than people expect: Mounjaro is once-weekly, and a delayed injection (say, four days late because of a bank holiday or a busy week) effectively gives the drug less time at steady-state. Consistency on the same day each week, even if that day shifts occasionally for practical reasons, keeps blood levels more stable.

Sleep and stress deserve a mention too. Both affect cortisol and hunger hormones in ways that can work against even a well-functioning GLP-1 medicine. This isn't a lifestyle lecture, it's just that tirzepatide doesn't override everything, and a patch of disrupted sleep during a stressful month can blunt apparent progress.

If you're wondering whether the issue is more about what happens at the next dose, the 7.5mg plateau question covers the pattern from that step onward. And if you started at 2.5mg and felt similarly stuck, the experience at that earlier dose is explored separately at the 2.5mg page.

On the cost side, some people considering whether to continue treatment at 5mg want to understand what they're paying and why, the Mounjaro pricing page covers the private market context honestly. What's rarely worth doing is pausing treatment to save money if you're genuinely progressing, even slowly; the clinical data consistently shows that weight loss accumulates over the full treatment period, not in the first two months. If you have already stepped up and are finding that 10mg isn't shifting the scales either, that page walks through the specific reasons progress can stall at that dose. Equally, if you have reached the top of the schedule and are asking why weight loss has slowed at 15mg, there is dedicated guidance on what to do at that stage.

When to raise it with your prescriber, and what to tell them

A few weeks of slower loss at 5mg is expected. Six to eight weeks with no change at all, no change in appetite, and no reduction in clothing size is worth discussing with a clinician. The NICE appraisal of tirzepatide notes that if less than 5% weight loss occurs after six months at the highest tolerated dose, continuing treatment should be reviewed, but six months at 5mg is not the same as six months overall, and the guidance is specifically about the highest tolerated dose, not an intermediate one. The NICE TA1026 recommendations are clear that titration upward is part of the expected pathway for most people.

When you speak to your prescriber, the most useful things to bring are: how many weeks you've been at 5mg, whether your appetite has noticeably changed, and whether you've had any side effects that are limiting how you eat. That's a short conversation with a lot of clinical value. Our prescribers review every repeat order individually, there's no algorithm reading your notes. If you'd like that review now, start your free consultation and a GPhC-registered prescriber will assess your situation the same day.